Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death

OncoImmunology

Volumn 3, Issue 4, 2014, Pages

  Golden, Encouse B ^a   Frances, Derek ^a   Pellicciotta, Ilenia ^a   Demaria, Sandra ^a   Barcellos Hoff, Mary Helen ^a   Formenti, Silvia C ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Carboplatin; Immunogenic cell death; Ionizing radiation; Oxaliplatin; Paclitaxel

Indexed keywords

ADENOSINE TRIPHOSPHATE; CALRETICULIN; CARBOPLATIN; HIGH MOBILITY GROUP B1 PROTEIN; OXALIPLATIN; PACLITAXEL;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CELL DEATH; CELL SURFACE; CHEMORADIOTHERAPY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; EXTRACELLULAR MATRIX; IMMUNE RESPONSE; IMMUNOGENIC CELL DEATH; IN VITRO STUDY; IONIZING RADIATION; PROTEIN TRANSPORT; RADIATION DOSE; RADIATION EXPOSURE;

EID: 84902517894     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.28518     Document Type: Article

References (38)

1. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013, 31, 51-72. PMID:23157435;http://dx.doi.org/10.1146/annurev-immunol-032712-100008
2. Kroemer G, Zitvogel L. Abscopal but desirable: The contribution of immune responses to the efficacy of radiotherapy. Oncoimmunology 2012, 1, 407-8. PMID:22754758;http://dx.doi.org/10.4161/onci.20074
3. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, Formenti SC. The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2012; 2:88; PMID:22891162; http://dx.doi.org/10.3389/fonc.2012.00088
4. Formenti SC, Demaria S. Systemic effects of local radiotherapy. Lancet Oncol 2009, 10, 718-26. PMID:19573801;http://dx.doi.org/10.1016/S1470-2045(09)70082-8
5. Formenti SC, Demaria S. Combining radiotherapy and cancer immunotherapy: a paradigm shift. J Natl Cancer Inst 2013, 105, 256-65. PMID:23291374;http://dx.doi.org/10.1093/jnci/djs629
6. Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An Abscopal Response to Radiation and Ipilimumab in a Patient with Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res 2013, 1, 365-72. http://dx.doi.org/10.1158/2326-6066.CIR-13-0115;PMID:24563870
7. Ma Y, Kepp O, Ghiringhelli F, Apetoh L, Aymeric L, Locher C, Tesniere A, Martins I, Ly A, Haynes NM, et al. Chemotherapy and radiotherapy: cryptic anticancer vaccines. Semin Immunol 2010, 22, 113-24. PMID:20403709;http://dx.doi.org/10.1016/j.smim.2010.03.001
8. Kroemer G, Adjemian S, Michaud M, Martins I, Kepp O, Sukkurwala AQ, Menger L, Vacchelli E, Ma Y, Zitvogel L. Contributions of immunogenic cell death to the efficacy of anticancer chemotherapy. Bull Mem Acad R Med Belg 2011; 166:130-8, discussion 139-40; PMID:22375493
9. Ma Y, Conforti R, Aymeric L, Locher C, Kepp O, Kroemer G, Zitvogel L. How to improve the immunogenicity of chemotherapy and radiotherapy. Cancer Metastasis Rev 2011, 30, 71-82. PMID:21298323;http://dx.doi.org/10.1007/s10555-011-9283-2
10. Locher C, Conforti R, Aymeric L, Ma Y, Yamazaki T, Rusakiewicz S, Tesnière A, Ghiringhelli F, Apetoh L, Morel Y, et al. Desirable cell death during anticancer chemotherapy. Ann N Y Acad Sci 2010, 1209, 99-108. PMID:20958322;http://dx.doi.org/10.1111/j.1749-6632.2010.05763.x
11. Tesniere A, Schlemmer F, Boige V, Kepp O, Martins I, Ghiringhelli F, Aymeric L, Michaud M, Apetoh L, Barault L, et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2010, 29, 482-91. PMID:19881547;http://dx.doi. org/10.1038/onc.2009.356
12. Obeid M, Panaretakis T, Joza N, Tufi R, Tesniere A, van Endert P, Zitvogel L, Kroemer G. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007, 14, 1848-50. PMID:17657249;http://dx.doi.org/10.1038/ sj.cdd.4402201
13. Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, Demaria S. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15, 5379-88. PMID:19706802;http://dx.doi. org/10.1158/1078-0432.CCR-09-0265
14. Demaria S, Ng B, Devitt ML, Babb JS, Kawashima N, Liebes L, Formenti SC. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated. Int J Radiat Oncol Biol Phys 2004, 58, 862-70. PMID:14967443;http://dx.doi. org/10.1016/j.ijrobp.2003.09.012
15. Pellegatti P, Falzoni S, Pinton P, Rizzuto R, Di Virgilio F. A novel recombinant plasma membrane-targeted luciferase reveals a new pathway for ATP secretion. Mol Biol Cell 2005, 16, 3659-65. PMID:15944221;http://dx.doi.org/10.1091/mbc.E05-03-0222
16. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008; 3:e2599; PMID:18612415; http://dx.doi.org/10.1371/journal. pone.0002599
17. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, Shen S, Kepp O, Scoazec M, Mignot G, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011, 334, 1573-7. PMID:22174255;http://dx.doi.org/10.1126/ science.1208347
18. Michalak M, Mariani P, Opas M. Calreticulin, a multifunctional Ca2+ binding chaperone of the endoplasmic reticulum. Biochem Cell Biol 1998, 76, 779-85. PMID:10353711;http://dx.doi. org/10.1139/bcb-76-5-779
19. Tesniere A, Panaretakis T, Kepp O, Apetoh L, Ghiringhelli F, Zitvogel L, Kroemer G. Molecular characteristics of immunogenic cancer cell death. Cell Death Differ 2008, 15, 3-12. PMID:18007663;http://dx.doi.org/10.1038/sj.cdd.4402269
20. Chaput N, De Botton S, Obeid M, Apetoh L, Ghiringhelli F, Panaretakis T, Flament C, Zitvogel L, Kroemer G. Molecular determinants of immunogenic cell death: surface exposure of calreticulin makes the difference. J Mol Med (Berl) 2007, 85, 1069-76. PMID:17891368;http://dx.doi.org/10.1007/ s00109-007-0214-1
21. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL, Castedo M, Mignot G, Panaretakis T, Casares N, et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007, 13, 54-61. PMID:17187072;http:// dx.doi.org/10.1038/nm1523
22. Zitvogel L, Kepp O, Senovilla L, Menger L, Chaput N, Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010, 16, 3100-4. PMID:20421432;http://dx.doi.org/10.1158/1078-0432.CCR-09-2891
23. Los GV, Wood K. The HaloTag: a novel technology for cell imaging and protein analysis. Methods Mol Biol 2007; 356:195-208; PMID:16988404
24. Martins I, Kepp O, Schlemmer F, Adjemian S, Tailler M, Shen S, Michaud M, Menger L, Gdoura A, Tajeddine N, et al. Restoration of the immunogenicity of cisplatin-induced cancer cell death by endoplasmic reticulum stress. Oncogene 2011, 30, 1147-58. PMID:21151176;http://dx.doi.org/10.1038/ onc.2010.500
25. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R, Mariette C, Chaput N, Mira JP, Delaloge S, et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007, 220, 47-59. PMID:17979839;http://dx.doi. org/10.1111/j.1600-065X.2007.00573.x 26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi. org/10.1016/0022-1759(83)90303-4
26. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 1983; 65:55-63; PMID:6606682; http://dx.doi.org/10.1016/0022-1759(83)90303-4
27. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH, Boyd MR. Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 1988; 48:589-601; PMID:3335022
28. Henriksson E, Kjellén E, Wahlberg P, Wennerberg J, Kjellström JH. Differences in estimates of cisplatininduced cell kill in vitro between colorimetric and cell count/colony assays. In Vitro Cell Dev Biol Anim 2006; 42:320-3; PMID:17316066
29. Puck TT, Marcus PI. Action of x-rays on mammalian cells. J Exp Med 1956, 103, 653-66. PMID:13319584;http://dx.doi.org/10.1084/jem.103.5.653
30. Martins I, Tesniere A, Kepp O, Michaud M, Schlemmer F, Senovilla L, Séror C, Métivier D, Perfettini JL, Zitvogel L, et al. Chemotherapy induces ATP release from tumor cells. Cell Cycle 2009, 8, 3723-8. PMID:19855167;http://dx.doi.org/10.4161/cc.8.22.10026
31. Barcellos-Hoff MH, Cordes N. Resistance to radioand chemotherapy and the tumour microenvironment. Int J Radiat Biol 2009, 85, 920-2. PMID:19895267;http://dx.doi.org/10.3109/09553000903274043
32. Russell JS, Brown JM. The irradiated tumor microenvironment:role of tumor-associated macrophages in vascular recovery. Front Physiol 2013; 4:157; PMID:23882218; http://dx.doi.org/10.3389/ fphys.2013.00157
33. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366, 925-31. PMID:22397654;http://dx.doi.org/10.1056/NEJMoa1112824
34. Sistigu A, Viaud S, Chaput N, Bracci L, Proietti E, Zitvogel L. Immunomodulatory effects of cyclophosphamide and implementations for vaccine design. Semin Immunopathol 2011, 33, 369-83. PMID:21611872;http://dx.doi.org/10.1007/ s00281-011-0245-0
35. Menger L, Vacchelli E, Adjemian S, Martins I, Ma Y, Shen S, Yamazaki T, Sukkurwala AQ, Michaud M, Mignot G, et al. Cardiac glycosides exert anticancer effects by inducing immunogenic cell death. Sci Transl Med 2012; 4:43ra99; PMID:22814852; http://dx.doi.org/10.1126/scitranslmed.3003807
36. Formenti SC, Demaria S. Effects of chemoradiation on tumor-host interactions: the immunologic side. J Clin Oncol 2008; 26:1562-3, author reply 1563; PMID:18349411; http://dx.doi.org/10.1200/ JCO.2007.15.5499
37. Formenti SC, Volm M, Skinner KA, Spicer D, Cohen D, Perez E, Bettini AC, Groshen S, Gee C, Florentine B, et al. Preoperative twice-weekly paclitaxel with concurrent radiation therapy followed by surgery and postoperative doxorubicin-based chemotherapy in locally advanced breast cancer: a phase I/II trial. J Clin Oncol 2003, 21, 864-70. PMID:12610186;http://dx.doi.org/10.1200/JCO.2003.06.132
38. Golden EB, Formenti SC; 2013 July 29. Assays and methods for assessing immunogenic cell death, efficacy of anti-cancer therapy and identifying potentially efficacious therapies. United States provisional patent Serial No. 61/859,351